Background: HIV infection is characterized by a state of chronic inflammation (CI). The degree to which combination antiretroviral therapy (cART) contributes to or ameliorates CI over time is unclear.
Methods: We measured levels of several inflammatory biomarkers (IB) in the 10 year period following initiation of cART in 327 patients participating in the Study to Understand the Natural History of HIV Infection in the Era of HAART (SUN Study) who had HIV-RNA levels < 200 copies/ml at each measurement. IB levels were measured in the specimen proximal to initiation of cART in 40 cART-naïve (cART-N) SUN Study patients and in a single specimen obtained from each of 30 case-matched HIV-negative controls (HNC). Baseline characteristics were similar between cART-experienced (cART-E) and cART-N groups. Frozen serum specimens were analyzed for RANTES, TNF-alpha, MIP-1 alpha and beta, MCP-1, and Interleukin (IL)-6, IL-7, and IL-15. In the cART-E group, IBs were measured at study entry, 2 years and 6 years. We stratified the 3 IB samples by number of years receiving continuous cART. We used the Kruskal-Wallis test of medians to compare IB levels from the cART-E vs. the cART-N and HNC groups.
Results: Over the 10 years following initiation of ART, IB levels in the cART-E group were significantly higher vs. those of HNCs (p < 0.05) excepting IL-7 which was not significantly different (NS) vs. HNCs. In the first 4-5 years IB levels in the cART-E groups initially rose and then declined to levels below those of the cART-N group but the differences were NS with the exception of MIP-1 alpha that was lower for the last 3 years and IL-6, IL-15, and MCP-1 that were lower in year 10 (p < 0.05, for all). For each year, there were no significant differences in IBs in the PI vs. NNRTI groups.
Conclusions: After 10 years of cART, levels of IBs decline but remain elevated vs. HNCs. There were no significant differences in levels seen with PI vs. NNRTI based cART.